Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-18 (canceled)

Claim 19 (new): A molecule of general formula (I), and the pharmaceutically acceptable salts thereof:

$$(X_0)_{x0}$$
- $(X_1)_{x1}$ - $(X_2)_{x2}$ - X_3 - $(X_4)_{x4}$ - X_5 - X_6 - $(X_7)_{x7}$ - $(X_8)_{x8}$ - $(X_9)_{x9}$
(I)

in which

- x0, x1, x2, x4, x7, x8 and x9 each represent, independently, an integer equal to 0 or to 1;

-X₀ represents a group chosen from those corresponding to formula (II):

in which Y represents a saturated or unsaturated, linear, branched or cyclic C_1 - C_{24} alkyl group, n represents an integer chosen from 0 and 1;

- -X₁ and X₃ each represent a natural or synthetic amino acid in the L or D configuration, each comprising at least one hydroxyl function on its side chain;
- -X₂ represents a natural or synthetic amino acid in the L or D configuration chosen from those comprising an alkyl side chain;
- -X₄ represents a natural or synthetic amino acid in the L or D configuration which can be chosen from those comprising an aromatic side chain;
- -X₅ represents an amino acid in the L or D configuration chosen from lysine, arginine, histidine, aspartic acid, asparagine, glutamic acid and glutamine;
- -X₆ represents an amino acid in the L or D configuration which can be chosen from tyrosine, phenylalanine, leucine, isoleucine, alanine, *para*-benzoylphenylalanine and lysine;
- -X₇ represents an amino acid in the L or D configuration which can be chosen from glycine, alanine, leucine, valine, asparagine and arginine;
- -X₈ represents an amino acid in the L or D configuration which can be chosen from proline, valine, isoleucine and aspartic acid;
- -X₉ represents an amino acid in the L or D configuration which can be chosen from serine, alanine, lysine, arginine and tryptophan;
- -the bond between two successive amino acids X_{i} - X_{i+1} , denoted $q_{i \text{ to } i+1}$, i=1 to 8 can be a peptide Q

bond – C– NH – or a pseudopeptide bond chosen from: CO-O, CO-S, CO-CH₂, CO-N(Me), NH-CO, CH=CH, CH₂-CH₂, CH₂-S, CH₂-O, CS-NH, CH₂-NH, CO-CH₂-NH, CO-NH-N= and CO-N(NH₂);

-the amino acids stated above X_i , i = 1 to 9 being capable of comprising a modification of their α -carbon, denoted C_i , i = 1 to 9 and bearing the side chain R of the amino acid, which modification consisting of the replacement of:



with a group chosen from:

the groups R and CH-R₁ representing the side chain of the amino acid and R_2 representing a C_1 - C_6 alkyl group; R- R_2 can constitute a ring,

-the pseudopeptides of the invention also corresponding to the following conditions:

x0 is equal to 1

or

one of the bonds $q_{i \text{ to } i+1}$, i = 1 to 8 is a pseudopeptide bond

or

one of the C_i , i = 1 to 9 comprises one of the modifications stated above.

Claim 20 (new): The molecule as claimed in claim 19, wherein one or more of the following conditions is verified:

at least one of the integers x0, x1, x2, x4, x7, x8 and x9 is equal to 1;

X₁ and X₃, which may be identical or different, are chosen from threonine and serine;

 X_2 is chosen from valine, leucine and isoleucine; or

 X_4 is chosen from phenylalanine, tryptophan, tyrosine and para-benzoylphenylalanine.

Claim 21 (new): The molecule as claimed in claim 20, comprising 4 to 8 amino acids.

Claim 22 (new): A molecule as claimed in claims 19 to 21, wherein x0 = 1 and the acyl chain -Y-CO- is a linear chain which is represented by the formula - C_pH_{2p} -CO-, p being an integer ranging from 1 to 23.

Claim 23 (new): The molecule as claimed in claim 22, wherein:

-when n = 1, Y represents $-C_pH_{2p}$ - and p can be 1, 2, 3, 4, 5, 6, 7 or 8; and

-when n = 0, Y represents - C_pH_{2p} - and p can be an integer ranging from 5 to 23.

Claim 24 (new): The molecule as claimed in claim 19, wherein one or more of the following conditions are verified:

- -at least one of X_1 and of X_3 represents threonine,
- -X₂ is chosen from isoleucine and valine,
- -X₄ is chosen from phenylalanine, tyrosine and para-benzoylphenylalanine, or
- -at least 2 of the integers x0, x1, x2, x4, x7, x8 and x9 are equal to 1.

Claim 25 (new): The molecule as claimed in claim 19, wherein the molecule corresponds to formula (la):

$$X_0-X_1-X_2-X_3-X_4-X_5-X_6$$
(Ia)

in which the bonds $q_{i to i+1}$ between the amino acids X_i and X_{i+1} , i = 1 to 5 are peptide or pseudopeptide bonds.

Claim 26 (new): The molecule as claimed in claim 25, wherein X_0 represents:

HN NH
$$S = \begin{bmatrix} C & H & (CpH_2p) & C & H & (CpH_2p) &$$

with p ranging from 1 to 8,

and X4 represents a para-benzoylphenylalanine group.

Claim 27 (new): The molecule as claimed in claim 25, wherein X₀ represents a group:

$$(C_p H_{2p+1}) - C -$$

with p ranging from 3 to 23.

Claim 28 (new): The molecule as claimed in claim 19, wherein the molecule corresponds to formula (lb):

$$X_3-X_5-X_6-X_7-X_8-X_9$$
(Ib)

in which:

-at least one of the bonds between two successive amino acids is a pseudopeptide bond, or

-one of the α -carbons of one of the amino acids is a modified α -carbon.

Claim 29 (new): The molecule as claimed in claim 19, wherein the molecule is:

 CH_3 -(C_nH_{2n})-CO-TVTYDY with n=4, 6, 8, 10, 12, 14, 16, 18;

 $CH_3-(C_nH_{2n})-CO-TISYDY$ with n=4, 6, 8, 10, 12, 14, 16, 18;

 CH_{3} -(C_nH_{2n})-CO-TVSYKF with n=4, 6, 8, 10, 12, 14, 16, 18;

 CH_3 - (C_nH_{2n}) -CO-TITFDY with n=4, 6, 8, 10, 12, 14, 16, 18;

 CH_{3} -(C_nH_{2n})-CO-TITYKF with n=4, 6, 8, 10, 12, 14, 16, 18;

 $CH_3-(C_nH_{2n})-CO-TITYEY$ with n=4, 6, 8, 10, 12, 14, 16, 18;

 CH_3 -(C_nH_{2n})-CO-TITYDF with n=4, 6, 8, 10, 12, 14, 16, 18;

 CH_3 - (C_nH_{2n}) -CO-TVTYKL with n=4, 6, 8, 10, 12, 14, 16, 18;

 CH_3 - (C_nH_{2n}) -CO-TVTYKY with n=4, 6, 8, 10, 12, 14, 16, 18;

 CH_3 -(C_nH_{2n})-CO-TVTFKF with n=4, 6, 8, 10, 12, 14, 16, 18;

 CH_{3} -(C_nH_{2n})-CO-TITYDL with n=4, 6, 8, 10, 12, 14, 16, 18;

 CH_3 -(C_nH_{2n})-CO-TVTFDY with n=4, 6, 8, 10, 12, 14, 16, 18;

```
CH_3-(C_nH_{2n})-CO-TVTFKF with n=4, 6, 8, 10, 12, 14, 16, 18;
CH<sub>3</sub>-(C<sub>n</sub>H<sub>2n</sub>)-CO-TVTYKF with n=4, 6, 8, 10, 12, 14, 16, 18;
Biot-Ava-TVT-Bpa-KF;
Biot-Ava-TVT-Bpa-KY;
Biot-Ava-TVT-Bpa-KL;
Biot-Ava-TVT-Bpa-DF;
Biot-Ava-TVT-Bpa-DY;
Biot-Ava-TVT-Bpa-DL;
Biot-Ava-TIT-Bpa-KF;
Biot-Ava-TIT-Bpa-KY;
Biot-Ava-TIT-Bpa-KL;
Biot-Ava-TIT-Bpa-DF;
Biot-Ava-TIT-Bpa-DY;
Biot-Ava-TIT-Bpa-DL;
Biot-Ava-TVT-Bpa-EF;
Biot-Ava-TVT-Bpa-EY;
Biot-Ava-TVT-Bpa-EL;
Biot-Ava-TIT-Bpa-EF;
Biot-Ava-TIT-Bpa-EY;
Biot-Ava-TIT-Bpa-EL;
Biot-Ava-TVT-Bpa-NF;
Biot-Ava-TVT-Bpa-NY;
Biot-Ava-TVT-Bpa-NL;
Biot-Ava-TIT-Bpa-NF;
Biot-Ava-TIT-Bpa-NY;
Biot-Ava-TIT-Bpa-NL;
TNL*GPS;
SEK*RVW;
TRA*LVR;
SNL*NDA; or
```

THI*VIK;

wherein Biot represents a biotinyl group,
Ava represents a δ-aminovaleric acid group,
Bpa represents a *para*-benzoylphenylalanine group; and wherein * represents:

-a bond chosen from ester, thioester, keto methylene, keto methyleneamino, N-methylamide, inverse amide, Z/E vinylene, ethylene, methylenethio, methyleneoxy, thioamide, methyleneamino, hydrazino, carbonylhydrazone and N-amino bonds, or -the presence of an aza-amino acid as a substitution for one of the amino acids adjacent to *.

Claim 30 (new): The molecule as claimed in claim 19 coupled on its C-terminal end and/or on its N-terminal end with another molecule which promotes its bioavailability.

Claim 31 (new): A composition comprising the molecule as claimed in claim 19 in a pharmaceutically acceptable carrier.

Claim 32 (new): A method for prevention and treatment of a disorder or a pathology associated with proteasome activity comprising administering to an animal in need thereof a molecule as claimed in claim 19.

Claim 33 (new): The method of claim 32, wherein the disorder or pathology is selected from: cancers involving hematological tumors or solid tumors; autoimmune diseases; AIDS; inflammatory diseases; cardiac pathologies; pathologies associated with the consequences of ischemic processes at the myocardial, cerebral or pulmonary level; allograft rejection; amyotrophy; cerebral strokes; traumas; burns; and pathologies associated with aging.

Claim 34 (new): A method for radiosensitizing a tumor comprising contacting the tumor with a compound as claimed in claim 19.

Claim 36 (new): A cosmetic process for preventing or treating the appearance of effects of chronological skin aging and/or of photoaging, comprising applying to skin the molecule as claimed claim 19 in a cosmetically acceptable carrier.

Claim 37 (new): The molecule as claimed in claim 21, wherein the molecule comprises 5 to 7 amino acids.

Claim 38 (new): The molecule as claimed in claim 21, wherein the molecule comprises 6 amino acids.

Claim 39 (new): The molecule as claimed in claim 24, wherein at least 3 of the integers x_0 , x_1 , x_2 , x_4 , x_7 , x_8 and x_9 are equal to 1.

Claim 40 (new): The molecule as claimed in claim 26, wherein p ranges from 2 to 6.

Claim 41 (new): The molecule as claimed in claim 27, wherein p ranges from 5 to 19.

Claim 42 (new): The method as claimed in claim 32, wherein the animal is a human.

Claim 43 (new): The method of claim 32, wherein the pathologies associated with aging Alzheimer's disease and Parkinson's disease.

Claim 44 (new): A method for modulating the proteasome of a cell comprising administering the molecule of claim 19 to a cell.

Claim 45 (new): The molecule as claim in claim 19, wherein X_1 and X_3 both represent threonine.